European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Biotech firm Nanogenics believes that its product LipTide could solve one of the oldest problems in gene therapy – delivery. Director of business development Alan Walker and director of pre-clinical development Simon Newman talk to PharmaTimes about their vision for the company and LipTide
Digitally-augmented multi-channel engagement has proved to be a useful approach for working with patients. However, it is easy for developers to default to a patient-facing website or an app that looks good and sounds impressive, but in practice doesn’t supply what patients want and need
The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.